B. Cepacia Hits ICUs Again, Raises Manufacturing Controls Questions
Executive Summary
Another outbreak of B. cepacia at hospital intensive care units in multiple states implicates manufacturing and supply chain controls on aqueous non-sterile drug products, particularly for those marketed over the counter under OTC monographs.
You may also be interested in...
US Warnings Show Focus On Sterility Risks From Water Systems Following OTC Drug Firm's Problems
A B. cepacia contamination recurrence led the US FDA to double down on sterility assurance of water systems in 2022, a trend likely to continue, Part 7 of our series finds. Open cleanroom contamination continued to drive warning letters as Annex 1 policy revision adds incentives to separate workers from injectable drug products with access barriers or isolators.
Warning Letters Special Report: A Focus On Sterility Risks From Water Systems, Open Cleanrooms
A B. cepacia contamination recurrence led the US FDA to double down on sterility assurance of water systems in 2022, a trend likely to continue, Part 7 of our series finds. Open cleanroom contamination continued to drive warning letters as Annex 1 policy revision adds incentives to separate workers from injectable drug products with access barriers or isolators.
Draft US FDA Guidance Outlines Heightened Expectations On Sterility Of Non-Sterile Drugs
More testing expected after B. cepacia contamination of OTC liquid drug products, including for Rx drug products.